A method of treating cancer is provided wherein the method comprises inhibiting or reducing sialylation of specifically Mesenchymal Stromal Cells (MSCs) to inhibit MSC immunosuppression and restore T cell proliferation in cancer. The method may comprise administering a sialyltransferase inhibitor (e.g. 3Fax-Peracetyl Neu5Ac) or sialidase. Also described is administration of MSCs which have been manipulated prior to administration to remove sialic acids and use of a small molecule or blocking antibody which blocks interactions between MSC-sialic acid and lectins, such as Siglec 7, and/or blocks interactions between MSC-lectins and sialic acid.

This document provides compounds of Formula (I), or pharmaceutically acceptable salts thereof, wherein D is a residue of a cytotoxic or chemotherapeutic compound, which undergoes hydrolysis under physiological conditions to release the cytotoxic or chemotherapeutic compound and which are useful in the treatment of cancer and other diseases.

##STR00001##

Provided are novel anti-SEZ6 antibodies and antibody drug conjugates, and methods of using such anti-SEZ6 antibodies and antibody drug conjugates to treat cancer.

In various embodiments nanoparticle drug delivery vehicles are provided that specifically deliver a cargo to a target pathogenic organism. In certain embodiments the drug delivery vehicle comprises a mesoporous silica nanoparticle comprising a plurality of pores and an outer surface through which the pores are disposed; a cargo disposed in the pores; one or more antigens attached to the surface of the nanoparticle; an antibody that specifically binds the antigens and are bound to the antigens, wherein the antibody inhibits diffusion of the cargo out of the pores and permit release of the cargo when the drug delivery vehicle is in the presence of the antigen or a pathogen displaying the antigen.

Disclosed herein is a method of facilitating the delivery of an agent across blood-brain barrier (BBB) of a subject. The method includes administering to the subject in sequence or concomitantly, an effective amount of a growth factor selected from the group consisting of, vascular endothelial growth factor (VEGF), insulin-like growth factor I (IGF-1), IGF-II, a portion thereof and a combination thereof; and an agent that is any of a therapeutic agent or an imaging agent. The administered amount of the growth factor is capable of transiently increasing BBB permeability of the subject and thereby allowing the agent to be delivered across BBB. Also disclosed herein is a method of treating a subject suffering from a brain tumor, a brain stroke, a neuropsychiatric disorder and/or a neurodegenerative disease.

This disclosure relates to an anti-Pseudomonas Psl binding molecule and uses thereof, in particular in prevention and treatment of Pseudomonas infection. Furthermore, the disclosure provides compositions and methods for preventing and treating Pseudomonas infection.

The invention relates generally to polypeptides that include a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator (uPA), to activatable antibodies and other larger molecules that include the cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator, and to methods of making and using these polypeptides that include a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator in a variety of therapeutic, diagnostic and prophylactic indications.

Methods for preparing a cell targeting conjugate, which conjugate comprises a cell binding moiety conjugated to a secondary functional moiety. The disclosure further relates to the cell targeting conjugates obtainable by the method, to a pharmaceutical composition comprising the conjugates and to the secondary functional moieties as such. The disclosure also relates to the use of the cell targeting conjugates in the treatment of cancer.

Various compositions are disclosed. The compositions of conjugates comprising immune-modulatory agents are also provided. Additionally provided are the methods of preparation and use of the conjugates. This includes methods for treating disorders, such as cancer and fibrosis.

Provided are a compound including a cleavable linker, a use thereof, and an intermediate compound for preparing the same, and more particularly, the compound including a cleavable linker of the present invention may include an active agent (for example, a drug, a toxin, a ligand, a probe for detection, etc.) having a specific function or activity, a SO.sub.2 functional group which is capable of selectively releasing the active agent, and a functional group which triggers a chemical reaction, a physicochemical reaction and/or a biological reaction by external stimulation, and may further include a ligand (for example, oligopeptide, polypeptide, antibody, etc.) having binding specificity for a desired target receptor.